Another worry is - rash incidence and severity with longer dosing might worsen. While anti-viral activity at 400mg BID will probably have strong efficacy, not sure if rash could be manageable. ANDS thinks, based on PK/PD analysis that loading dose followed by reduced doses can do the trick but ANA598 chances to be successfully developed don't look too good for now.
Market Data 
Markets 
AI
